We provide a better understanding of the molecular mechanisms underlying this interaction may contribute to the development of novel therapeutic strategies targeting HDAC5 and MEF2A for the treatment of heart failure and other cardiovascular diseases. The gene discussed is MEF2A; the disease is heart failure.